MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from the pipe
financings, net
$169,644K
Proceeds from issuance of
common stock upon...
$671K
Net cash provided by
financing activities
$170,315K
Net (decrease)
increase in cash and cash...
-$14,640K
Canceled cashflow
$170,315K
Proceeds from maturities
of marketable...
$424,423K
Stock-based compensation
expense
$24,240K
Accrued expenses and
other current...
$7,245K
Accounts payable
$693K
Non-cash lease expense
$458K
Depreciation expense
$83K
Net cash used in
investing activities
-$96,745K
Canceled cashflow
$424,423K
Net cash used in
operating activities
-$88,210K
Canceled cashflow
$32,719K
Purchases of marketable
securities
$520,959K
Purchases of property and
equipment
$209K
Net loss
-$105,433K
Related party accounts
payable and other...
-$6,013K
Net accretion of
premiums and discounts on...
$5,003K
Prepaid expenses and
other current assets
$3,972K
Operating lease liability
-$448K
Other non-current
assets
$60K
Back
Back
Cash Flow
source: myfinsight.com
Oruka Therapeutics, Inc. (ORKA)
Oruka Therapeutics, Inc. (ORKA)